FDA clears Botox for chronic migraine, but cost may be prohibitive for some
This article was originally published in Scrip
Executive Summary
The US FDA has approved a supplemental indication for Allergan's Botox (botulinum toxin A) to prevent headaches in adults with chronic migraine – or those who suffer 15 or more headaches per month lasting four hours a day or longer. The decision, although widely expected following an earlier approval in the UK in July, added 5% to Allergan's stock value and appears to justify the risks the company took in expanding Botox' off-label uses.